VPAC2 Agonists Neuroprotective and Anti-inflammatory Effects in Parkinson's Disease
Research Grant, 2015
Study Rationale: † † † † † † † † ††
The adaptive and innate immune responses play intricate roles in modulating neuroinflammation and may be harnessed for neuroprotection from Parkinsonís disease. We have developed a novel modulator (VPAC2 agonist) that transforms adaptive immune activities from neurotoxic to neurotrophic (supporting growth). This project aims to determine pharmacokinetic and pharmacodynamics parameters of the VPAC2 agonist, including formulation of dose response and blood-brain-barrier penetrance. We will also determine preliminary cardiovascular safety risk factors. †
This study aims to determine key mechanisms and safety of a Parkinsonís disease therapeutic drug candidate.
We will perform detailed immunological experiments to determine neuroprotective endpoints. Ultimately, direct protection of neurons will enable confirmation of the disease-modifying potential of the VPAC2 agonist. We will also complete FDA-quality preliminary pharmacokinetic evaluations and key cardiovascular safety studies. †
Impact on Diagnosis/Treatment of Parkinsonís Disease: † † † † † ††
Addressing brain inflammation, such as in this study, has the potential to slow or stop neurodegeneration seen in Parkinsonís and could possibly result in stabilization of symptoms and disease progression. †
Next Steps for Development:
Should this project confirm cardiovascular safety and further determine key inflammatory markers of Parkinsonís disease, our next steps would be to accelerate this program towards clinical evaluation. We would initiate FDA-mandated investigational new drug studies, and clinical trials would follow.
CEO at Longevity Biotech, Inc.
Location: Philadelphia, Pennsylvania, United States
Margaret R. Larson Professor of Internal Medicine and Infectious Diseases, and Chair of the Department of Pharmacology and Experimental Neuroscience at University of Nebraska Medical Center
Location: Omaha, Nebraska, United States